To compare the image-based three-dimensional treatment planning using AcurosTM BV and AAPM TG-43 algorithm for intracavitary brachytherapy of carcinoma cervix.

Twenty-seven patients with cancer cervix, stage IIB or IIIB with vaginal involvement limited to the upper third of the vagina was included into the study. Intracavitary treatments with the patient in this study done with computed tomography and magnetic resonance imaging compatible ring applicator. Groupe European de Curietherapie and European Society for Therapeutic Radiology and Oncology recommended doses to target volumes and organs at risk compared using dose volume histogram.

The mean value of Point ‘A’ dose was compared between AcurosTM BV and TG-43, which indicates 0·13% difference. The differences in the mean dose to gross tumour volume for various volumes are V100% 0·28%, V150% 1·22% and V200% 1·03%; all volumes showed small difference but statistical significant (p<0·05). The mean dose of high-risk clinical target volume (HRCTV) D90 using AcurosTM BV was 8·47 Gy, which was 1·63% less compared with TG-43. The mean point A dose using AcurosTM BV is 1·04 times the dose to D90 of mean HRCTV. The same difference was observed in comparison with TG43. D2cc and D0·1cc of the bladder, rectum and sigmoid showed a statistically significant difference (p<0·05) in comparison with TG-43.

The differences in dosimetric parameters between the AcurosTM BV and TG-43 proved to be statistically significant. The difference is very small, and they are clinically insignificant.